Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021
March 22 2021 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that it will
release financial results for the three and 12 months ended
December 31, 2020 after the market closes on Monday, March 29,
2021. The Company will host a conference call for the investment
community to discuss the results and answer questions at 4:30 p.m.
Eastern time (1:30 p.m. Pacific time).
Date/Time:
Monday, March 29, 4:30 p.m. ET / 1:30 p.m.
PT
Pre-Registration:
Participants can pre-register for the
conference call here.
Callers who pre-register will be given a
conference passcode and unique PIN to gain immediate access to the
call and bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time.
Dial In:
Those who choose not to pre-register can
access the live conference call by dialing the following and
requesting the Biocept call:
U.S. Callers:
855-656-0927
Canadian Callers:
855-669-9657
Other International Callers:
412-902-4109
A live webcast of the call will be available at
https://ir.biocept.com/. The webcast will be archived for 90
days.
A replay of the conference call will be available for 48 hours
following the conclusion of the call by dialing (877) 344-7529 for
domestic callers, (855) 669-9658 for Canadian callers, or (412)
317-0088 for other international callers, and entering the replay
access code 10152872.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept is developing and
commercializing cerebrospinal fluid (CSF) assays that detect cancer
that has metastasized to the central nervous system. The Company’s
CSF assays identify molecular targets for clinical decision making
and provide quantitative information for monitoring treatment
response. Biocept’s patented Target Selector™ technology platform
captures and analyzes tumor-associated molecular markers in both
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)
with higher sensitivity and specificity than most commercial
assays. Additionally, Biocept is leveraging its molecular
diagnostic capabilities to offer nationwide COVID-19 PCR testing to
support public health efforts during this unprecedented pandemic.
For additional information, visit www.biocept.com. Follow Biocept
on Facebook, LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210322005088/en/
LHA Investor Relations Jody Cain Jcain@lhai.com
310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024